Once primarily associated with diabetes and obesity, GLP-1 drugs are now being explored for their potential to treat a range of conditions including heart and kidney disease, sleep apnoea, cancer, and addiction, signalling a significant shift in their clinical use.
The public conversation around GLP-1 medicines has moved well beyond weight loss. What began as a class of drugs mainly associated with diabetes treatment and obesity management is now being studied for possible effects on the heart, kidneys, liver, sleep, substance use and cancer risk, according to reporting cited in FODMAP Everyday and supporting medical sources.
That wider interest is rooted in how the drugs work. GLP-1, or glucagon-like peptide-1, is a hormone involved in blood sugar regulation and appetite control, and GLP-1 receptor agonists imitate its action. Because receptors are found in multiple organs, researchers have been exploring whether the medicines can influence systems well beyond metabolism. The National Kidney Foundation says they may help slow chronic kidney disease in some patients and reduce cardiovascular risk, while also noting that treatment decisions still require careful medical review.
Some of the most concrete advances have already reached routine care. The U.S. Food and Drug Administration has approved Zepbound, which acts on both GLP-1 and GIP pathways, as the first medication for moderate to severe obstructive sleep apnoea in adults with obesity. The agency has also backed uses for several GLP-1 drugs in heart and kidney disease, reflecting a shift from viewing them as narrow weight-loss tools to recognising broader clinical benefits.
Researchers are still trying to separate the effect of weight reduction from other biological mechanisms. A study co-authored by Yale’s Harlan Krumholz found tirzepatide lowered systolic blood pressure by nearly seven points compared with placebo, while other work has suggested semaglutide may reduce cardiovascular inflammation even without major weight loss. Krumholz told Today that the benefits are not fully explained by shedding pounds alone.
Interest has also turned to cancer and addiction, two areas where the evidence is promising but far from settled. Early studies have reported lower rates of obesity-related cancers among some users, and researchers presenting work at the American Society of Clinical Oncology annual meeting said women with excess weight who used GLP-1 medicines were less likely to develop breast cancer. Separate trials have hinted at reduced alcohol cravings and consumption, and research in veterans with Type 2 diabetes has linked GLP-1 use with lower risks of several substance-use disorders. But scientists caution that none of this makes the drugs established treatments for cancer prevention or addiction.
The enthusiasm comes with familiar caveats. The most common side effects are gastrointestinal, including nausea, diarrhoea, constipation and vomiting, and more serious concerns can include pancreatitis, gallbladder problems and possible thyroid tumours. Cost and insurance coverage remain major barriers, especially when the drugs are considered for uses outside their current approvals. For now, the biggest question is not whether GLP-1 medicines can help people lose weight, but which patients benefit most, at what dose and for how long.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
